Gustave Roussy immune score as an independent prognostic factor for treatment response and survival in advanced renal cell carcinoma treated with nivolumab in second-line and beyond.

ABSTRACT:

Background

Metastatic renal cell carcinoma (mRCC) represents a significant challenge due to variable patient outcomes despite advancements in treatment. Nivolumab, a programmed death-1 (PD-1) inhibitor, has demonstrated efficacy as a second-line or later therapy following progression on tyrosine kinase inhibitors (TKIs). However, identifying reliable prognostic biomarkers remains critical. The Gustave Roussy Immune (GRIm) score, incorporating serum albumin, lactate dehydrogenase (LDH), and neutrophil-to-lymphocyte ratio (NLR), may provide prognostic value in this context.

Methods

This multicenter retrospective cohort study included 81 mRCC patients treated with nivolumab as second-line or subsequent therapy following progression on first-line TKIs (e.g., sunitinib or pazopan

SUBMITTER: Erdogan B 

PROVIDER: S-EPMC12571565 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature